Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes in Malaysia: Results from a Prospective, Non-interventional Real-World Study

被引：1

作者：

Mohamed, Mafauzy ^{[1
,16
]}

Lim, Siang Chin ^{[2
]}

Mumtaz, Malik ^{[3
]}

Uppal, Shweta ^{[4
]}

Mukherjee, Deepak ^{[4
]}

Kassim, Mohamed Saiful Mohd ^{[5
]}

Sreedharan, Shalini ^{[6
]}

Doraiswamy, Amudha Murugan ^{[7
]}

Chong, Kuck Meng ^{[8
]}

Tat, Lu Yu ^{[9
]}

Nordin, Sudzilla Binti ^{[10
]}

Giek, Jeshen Lau Hui ^{[11
]}

Hussein, Zanariah ^{[12
]}

Kadir, Khalid Abdul ^{[13
]}

Lau, Bik Kui ^{[14
]}

Chan, Siew Pheng ^{[15
]}

机构：

[1] Univ Sains Malaysia, Kota Baharu, Kelantan, Malaysia

[2] Mahkota Med Ctr, Melaka, Malaysia

[3] Isl Hosp, George Town, Penang, Malaysia

[4] Novo Nordisk Pharm Malaysia Sdn Bhd, Kuala Lumpur, Malaysia

[5] Gleneagles Hosp Kuala Lumpur, Kuala Lumpur, Malaysia

[6] Pantai Hosp Sungai Petani, Sungai Petani, Kedah, Malaysia

[7] Pantai Hosp, Ayer Keroh, Melaka, Malaysia

[8] Klin Chong Slim River, Slim River, Perak, Malaysia

[9] Klin Remed, Kangar, Perlis, Malaysia

[10] Kota Bharu Med Ctr, Kota Baharu, Kelantan, Malaysia

[11] Borneo Med Ctr, Kuching, Sarawak, Malaysia

[12] Putrajaya Hosp, Putrajaya, Malaysia

[13] Thomson Hosp Kota Damansara, Petaling Jaya, Selangor, Malaysia

[14] KPJ Kuching Specialist Hosp, Kuching, Sarawak, Malaysia

[15] Subang Jaya Med Ctr, Subang Jaya, Selangor, Malaysia

[16] Univ Sains Malaysia, Hosp Univ Sains Malaysia, Kampus Kesihatan,Jalan Raja Perempuan Zainab 2, Kota Baharu 16150, Kelantan, Malaysia

来源：

JOURNAL OF THE ASEAN FEDERATION OF ENDOCRINE SOCIETIES | 2023年 / 38卷 / 01期

关键词：

type 2 diabetes mellitus; insulin degludec; insulin aspart; Malaysia; hypoglycemia; TREATMENT INTENSIFICATION; BASAL; EFFICACY; SAFETY; TRIAL;

D O I：

10.15605/jafes.038.01.12

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objectives. Insulin degludec (IDeg)/insulin aspart (IAsp; IDegAsp) is a co-formulation of 70% IDeg and 30% IAsp. According to several randomized controlled trials, IDegAsp is effective and safe for patients with type 2 diabetes mellitus (T2DM). A subgroup analysis of the ARISE study was conducted to explore the safety and efficacy of IDegAsp among Malaysian patients with T2DM in real-world settings.Methodology. ARISE, an open-label, multicenter, non-interventional, prospective study was conducted between August 2019 and December 2020. Adult Malaysian patients with T2DM who were enrolled from 14 sites received IDegAsp as per the local label for 26 weeks. The primary endpoint was change in glycated hemoglobin (HbA1c) levels from baseline to end of study (EOS).Results. Of the 182 patients included in the full analysis set, 159 (87.4%) completed the study. From baseline to EOS, HbA1c (estimated difference [ED]: -1.3% [95% CI: -1.61 to -0.90]) and fasting plasma glucose levels (ED: -1.8 mmol/L [95% CI: -2.49 to -1.13]) were significantly reduced (p<0.0001). The patient-reported reduced hypoglycemic episodes (overall and nocturnal) during treatment. Overall, 37 adverse events were observed in 23 (12.6%) patients.Conclusion. Switching or initiating IDegAsp treatment resulted in significant improvements in glycemic control and a reduction in hypoglycemic episodes.

引用

页码：37 / 44

页数：8